Table 2.
Participant Medication Use by HIV Serostatus
| Reported Number of Medications Used, N (%) | HIV+ (N=1,315) | HIV− (N=557) | P-Value |
|---|---|---|---|
| Total non-antiretroviral medications | 0.0002 | ||
| 0–4 | 648 (49.3) | 329 (59.1) | |
| 5–9 | 433 (32.9) | 161 (28.9) | |
| 10+ | 234 (17.8) | (12.0) | |
| Neurocognitive adverse effect (NCAE) medications | 0.01 | ||
| 0 | 732 (55.7) | 349 (62.7) | |
| 1 | 288 (21.9) | 95 (17.1) | |
| 2 | 295 (22.4) | 113 (20.3) | |
| NCAE medication type | |||
| Anxiolytics | 145 (11.0) | 57 (10.2) | 0.61 |
| Anticholinergics | 350 (26.6) | 133 (23.8) | 0.95 |
| Anticonvulsants | 59 (4.5) | 26 (4.7) | 0.86 |
| Antipsychotics | 92 (7.0) | 45 (8.1) | 0.41 |
| Amphetamines | 7 (0.5) | 2 (0.4) | 0.62 |
| Opioids | 160 (12.2) | 57 (10.2) | 0.23 |
| Beta blockers | 40 (3.0) | 16 (2.9) | 0.84 |
| Gastrointestinal agents | 34 (2.6) | 12 (2.2) | 0.58 |
| Antihistamines | 115 (8.7) | 45 (8.1) | 0.64 |
| Muscle relaxants | 53 (4.0) | 31 (5.6) | 0.14 |
| Antidepressants | 283 (21.5) | 72 (12.9) | <0.001 |
| Anti-COPD* | 33 (2.5) | 18 (3.2) | 0.38 |
*
Chronic Obstructive Pulmonary Disease